The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Editorials

Bioresorbable scaffolds and STEMI: an ideal setting, but still vacant

EuroIntervention 2020;15:1397-1399. DOI: 10.4244/EIJV15I16A254

1. Department of Cardiology, European Hospital Georges Pompidou, Assistance Publique Hôpitaux de Paris, Paris Descartes University, Sudden Cardiac Death Expert Center, Paris, France


Only a few years ago, bioresorbable scaffolds (BRS) were the “prima donnas” of interventional cardiology meetings and journals. They held the promise of transforming the treatment of coronary artery disease by providing a temporary scaffold during the initial healing period and, once resorbed, allowing the return of normal vascular vasomotion. The Food and Drug Administration (FDA) approved the Absorb™ bioresorbable vascular scaffold (BVS) stent (Abbott Vascular, Santa Clara, CA, USA) in 2016. Alas, in 2017 the FDA issued a warning letter due to an excess of late device thrombosis and major adverse cardiovascular events and Abbott withdrew the ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article

Stroke after transcatheter edge-to-edge mitral valve repair: a systematic review and meta-analysis